Subcutaneous injection (clinical trials and biohacker use)
Half-life
~2–3 hours in plasma; concentrates rapidly in mitochondria
Most studied use
Cardiac protection and heart failure · Primary mitochondrial disease · Mitochondrial aging · Energy and physical performance
Regulatory status
Not FDA-approved · Phase III trial (EMBARK) completed for Barth syndrome · Phase II trials for heart failure, macular degeneration, primary mitochondrial myopathy · Research chemical
Human evidence
Strong mechanistically — Phase II/III data in disease populations; limited healthy adult data
Preclinical evidence
Exceptional — one of the most studied mitochondria-targeting peptides; extensive cardiac, kidney, and aging models
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is SS-31?
SS-31 (elamipretide) occupies a unique position in the peptide space: it's one of the few compounds in this guide that was purpose-engineered to target mitochondria directly. Where most peptides act through cell-surface receptors, SS-31 crosses cell membranes and concentrates in the inner mitochondrial membrane — specifically binding cardiolipin, a phospholipid essential for the electron transport chain. This targeted mitochondrial action makes SS-31 the most mechanistically specific mitochondrial intervention available, distinct from MOTS-c (which signals from mitochondrial DNA) and NAD+ precursors (which fuel mitochondrial enzymes).
Cardiolipin is the structural and functional foundation of the inner mitochondrial membrane. It stabilizes the electron transport chain complexes, maintains the proton gradient necessary for ATP synthesis, and protects cytochrome c from being released as an apoptosis signal. With aging and cellular stress, cardiolipin oxidizes and its protective function degrades — contributing to mitochondrial dysfunction, reduced ATP production, and increased oxidative stress. SS-31 binds cardiolipin, prevents its oxidation, and restores ETC function.
The clinical evidence is strongest in cardiovascular disease. Phase II trials in heart failure with preserved ejection fraction (HFpEF) showed significant improvements in 6-minute walk distance and exercise capacity. A Phase III trial (EMBARK) in Barth syndrome — a rare genetic mitochondrial disease — met its primary endpoint. This is a compound with genuine clinical trial history, not just preclinical data. For biohackers, the application is mitochondrial optimization: better energy production, improved exercise capacity, and potentially slowed mitochondrial aging — extrapolated from disease-population data to healthy adults.
How it works
Cardiolipin Binding and ETC Protection
SS-31's primary mechanism is binding to cardiolipin in the inner mitochondrial membrane. Cardiolipin serves as an organizational anchor for ETC complexes I, III, IV, and V, maintaining the curvature and integrity of the inner membrane and sequesters cytochrome c. SS-31's binding: protects cardiolipin from peroxidation by reactive oxygen species, maintains the mitochondrial membrane potential, and stabilizes cytochrome c — keeping it in the ETC rather than releasing it as an apoptosis signal.
Electron Transport Chain Enhancement and ROS Reduction
By stabilizing cardiolipin and ETC complex assembly, SS-31 improves electron flow through the ETC, increases ATP production efficiency, and reduces electron leak (which produces superoxide). The net effect: more ATP from the same substrate, less oxidative stress as a byproduct. SS-31's alternating cationic and aromatic amino acids also give it intrinsic free radical scavenging activity — dual mechanism of structural protection AND direct ROS scavenging.
Aging and Mitochondrial Dysfunction
Mitochondrial dysfunction is one of the nine hallmarks of aging. Cardiolipin oxidation and ETC dysfunction accumulate with age in all tissues — heart, brain, skeletal muscle, kidney. Animal models show SS-31 reverses many of these age-related mitochondrial changes: improved ETC function, restored ATP production, reduced mitochondrial ROS, and improved function in aged cardiac and skeletal muscle. These findings are the basis for the longevity and healthy aging applications.
What the research shows
HUMAN AND PRECLINICAL EVIDENCE
STUDYJACC: Heart Failure · 2021
Elamipretide in Heart Failure with Preserved Ejection Fraction — Phase II
Dauber IM et al.
Phase II RCT. Elamipretide significantly improved 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire scores vs. placebo in HFpEF patients. Significant improvement in mitochondrial function biomarkers. Key clinical evidence in a disease population.
Elamipretide in Primary Mitochondrial Myopathy — Phase II
Karaa A, Haas R, Goldstein A et al.
Open-label Phase II. Significant improvements in muscle strength, fatigue, and mitochondrial function biomarkers in adults with primary mitochondrial myopathy. Established safety and tolerability profile.
SS-31 Reverses Mitochondrial Dysfunction and Rescues Diastolic Function in Aging
Chiao YA, Zhang H, Sweetwyne M et al.
Aged mice. SS-31 reversed mitochondrial dysfunction in aged cardiac muscle, improved diastolic function, and reduced ROS. Key aging model evidence supporting the anti-aging application extrapolated to biohacker healthy adult use.
?Interaction effects with exercise and other mitochondrial interventions
?Whether subjective energy improvements translate to objective performance metrics in healthy adults
What the community reports
—Improved energy and reduced fatigue — the most consistently reported effect; described as cleaner and more sustained; typically noticeable within 1–2 weeks
—Exercise performance improvement — endurance specifically; faster recovery between sessions
—Cognitive clarity — improved mental energy alongside physical energy; consistent with mitochondrial function improvements in brain tissue
—The mitochondrial longevity stack: SS-31 + MOTS-c + NAD+ — three-pronged mitochondrial optimization, each targeting a different mechanism
—Subtle but consistent improvement — effects are more gradual than compounds with acute subjective impact; careful tracking over weeks reveals meaningful changes
—Clean side-effect profile — injection site reactions occasionally; otherwise minimal
Common misconceptions
"SS-31 is just another antioxidant."
REALITY
SS-31 specifically targets and concentrates in the inner mitochondrial membrane — accumulating several hundred-fold compared to cytosolic concentrations. Its cardiolipin-binding, ETC-stabilizing mechanism is categorically different from systemic antioxidants like vitamin C or NAD+. It's a mitochondrial structural protectant, not a general antioxidant.
"If it works in heart failure, it will definitely work in healthy people."
REALITY
Compounds that rescue severely dysfunctional mitochondria don't necessarily produce proportional benefits in healthy mitochondria. The question of whether SS-31 optimizes healthy mitochondria or primarily rescues damaged ones is not resolved. The animal aging models are encouraging; healthy human data is limited.
"SS-31 is nearly FDA-approved."
REALITY
The Phase III EMBARK trial in Barth syndrome was completed, but FDA approval requires a complete application and regulatory review — that process is still underway as of mid-2026. For HFpEF and other indications, Phase III has not been completed. FDA approval is not imminent for any indication.
MITOCHONDRIAL STACK
SS-31 (inner membrane structural protection) pairs with MOTS-c (AMPK activation, metabolic signaling) and NAD+ (sirtuin activation, ETC enzyme fuel). Three different entry points into mitochondrial health — complementary, not redundant.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want to add SS-31 to my MOTS-c and NAD+ stack. What dose and timing makes sense for energy optimization?
The SS-31 + MOTS-c + NAD+ stack is the most mechanistically coherent mitochondrial optimization combination available — each compound addresses a different layer of mitochondrial function. Here's how to integrate SS-31 specifically. Mechanism orientation: SS-31 protects the structural integrity of the inner mitochondrial membrane by binding cardiolipin — it prevents the cardiolipin oxidation that degrades ETC complex function with age and stress. MOTS-c activates AMPK and improves metabolic signaling. NAD+/NMN fuels the sirtuin and ETC enzyme systems. These are genuinely different mechanisms at different levels of the same system. Dose: 1–2 mg subcutaneous daily. The Phase II HFpEF trial used weight-based dosing (0.05–0.25 mg/kg), which for most users translates to 3.5–17.5 mg — higher than community biohacker dosing. The community converges on 1–5 mg daily, with 2 mg being the most common midpoint. Start at 1 mg and assess over 2–3 weeks. Timing: morning — energy enhancement aligns with daytime metabolic activity. No strong argument for specific meal timing; inject and proceed with your day. With your existing stack: run simultaneously. No known interactions between SS-31, MOTS-c, and NAD+ precursors — the mechanisms are complementary and additive in theory. Cycle: 4–8 weeks on, 2–4 weeks off. What to track: daily energy rating (consistent scale, same time each morning), exercise performance metric (something objective you can repeat weekly — time trial, grip strength, training volume), and resting heart rate if you track it (an indirect signal for cardiovascular efficiency). SS-31 effects are gradual — you're looking for a trend over weeks, not an acute subjective shift like you'd feel from caffeine or even ipamorelin. The community is consistent on this: the energy improvement is real but builds over time. Don't assess at 1 week. Assess at week 4. What does your current MOTS-c and NAD+ protocol look like — doses and timing?
CONTINUE IN THE APP
Open PepperLedger to track your SS-31 protocol →
Free to join. No credit card. Ask the Coach about your mitochondrial stack once you're in.
Free to join · No credit card · 23-day Pro trial included